ENOV Logo

Enovis Corporation (ENOV) Stock Forecast & Price Prediction

Live ENOV Stock Price & Analysis

Home Stocks United States | NYSE | Industrials | Specialty Industrial Machinery

$44.00

-0.74 (-1.65%)

12 Month Price Forecast For ENOV

$44.00
Current Price
$2.54B
Market Cap
11 Ratings
Buy 10
Hold 1
Sell 0
Wall St Analyst Ratings

Distance to ENOV Price Forecasts

+70.5%
To High Target of $75.00
+44.3%
To Median Target of $63.50
+13.6%
To Low Target of $50.00

ENOV Price Momentum

-6.3%
1 Week Change
-3.9%
1 Month Change
-27.3%
1 Year Change
+0.3%
Year-to-Date Change
-32.3%
From 52W High of $65.03
+15.0%
From 52W Low of $38.27

🤔 Considering Enovis (ENOV)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 10:49 AM UTC

ENOV Analyst Ratings & Price Targets

Based on our analysis of 17 Wall Street analysts, ENOV has a consensus that is bullish. The median price target is $63.50, with forecasts ranging from $50.00 to $75.00. Currently, there are 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings.

With ENOV currently trading at $44.00, the median price forecast suggests a 44.3% upside. The most optimistic forecast comes from Caitlin Cronin at Canaccord Genuity, projecting a 70.5% upside, while Robbie Marcus at JP Morgan provides the most conservative target, suggesting a 13.6% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

ENOV Analyst Consensus

10
Buy
1
Hold
0
Sell

ENOV Price Target Range

Low
$50.00
Average
$63.50
High
$75.00
Current: $44.00

Latest ENOV Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for ENOV.

Date Firm Analyst Rating Change Price Target
Nov 7, 2024 Needham Mike Matson Buy Reiterates $65.00
Oct 3, 2024 JMP Securities David Turkaly Market Outperform Initiates $62.00
Oct 1, 2024 Evercore ISI Group Vijay Kumar Outperform Maintains $58.00
Aug 8, 2024 JP Morgan Robbie Marcus Neutral Maintains $50.00
Aug 8, 2024 Needham Mike Matson Buy Maintains $65.00
Jul 2, 2024 Evercore ISI Group Vijay Kumar Outperform Maintains $62.00
Jun 13, 2024 JP Morgan Robbie Marcus Neutral Initiates $53.00
May 3, 2024 Needham Mike Matson Buy Reiterates $82.00
Apr 10, 2024 Needham Mike Matson Buy Reiterates $82.00
Feb 23, 2024 Wells Fargo Vik Chopra Overweight Maintains $79.00
Feb 23, 2024 Canaccord Genuity Caitlin Cronin Buy Maintains $75.00
Feb 23, 2024 Needham Mike Matson Buy Maintains $82.00
Feb 13, 2024 Stephens & Co. George Sellers Overweight Initiates $72.00
Jan 22, 2024 UBS Danielle Antalffy Buy Initiates $75.00
Jan 8, 2024 Needham Mike Matson Buy Maintains $73.00
Jan 3, 2024 William Blair Brandon Vazquez Outperform Initiates $0.00
Dec 20, 2023 Canaccord Genuity Kyle Rose Buy Maintains $71.00
Dec 15, 2023 Needham Mike Matson Buy Maintains $70.00
Nov 8, 2023 Needham Mike Matson Buy Maintains $62.00
Oct 20, 2023 Needham Mike Matson Buy Reiterates $70.00

Stocks Similar to Enovis Corporation

The following stocks are similar to Enovis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Enovis Corporation (ENOV) Financial Data

Enovis Corporation has a market capitalization of $2.54B with a P/E ratio of -72.1x. The company generates $2.00B in trailing twelve-month revenue with a -6.0% profit margin.

Revenue growth is +21.0% quarter-over-quarter, while maintaining an operating margin of +1.2% and return on equity of -3.6%.

Valuation Metrics

Market Cap $2.54B
Enterprise Value $3.88B
P/E Ratio -72.1x
PEG Ratio 14.2x
Price/Sales 1.3x

Growth & Margins

Revenue Growth (YoY) +21.0%
Gross Margin +56.7%
Operating Margin +1.2%
Net Margin -6.0%
EPS Growth +21.0%

Financial Health

Cash/Price Ratio +1.4%
Current Ratio 2.3x
Debt/Equity 42.4x
ROE -3.6%
ROA +0.4%

🔥 Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Enovis Corporation logo

Enovis Corporation (ENOV) Company Overview

About Enovis Corporation

What They Do

Medical technology company developing innovative solutions.

Business Model

Enovis Corporation generates revenue through the manufacture and distribution of medical devices for reconstructive surgery, rehabilitation, and pain management. It operates in two main segments: Prevention and Recovery, which offers a variety of orthopedic and recovery solutions, and Reconstructive, which focuses on surgical implants and productivity tools. The company sells its products through independent distributors and directly under its ESAB and DJO brands.

Additional Information

Founded in 1995 and headquartered in Wilmington, Delaware, Enovis Corporation was previously known as Colfax Corporation. The company serves a wide range of healthcare professionals including orthopedic specialists, surgeons, and physical therapists, positioning itself as a key player in the medical technology sector.

Company Information

Sector

Industrials

Industry

Specialty Industrial Machinery

Employees

6,550

CEO

Mr. Matthew L. Trerotola

Country

United States

IPO Year

2022

Enovis Corporation (ENOV) Latest News & Analysis

ENOV stock latest news image
Quick Summary

Enovis, Omnicell, and Phreesia are featured in an Industry Outlook article, indicating potential relevance for investors in the healthcare and technology sectors.

Why It Matters

Highlighting Enovis, Omnicell, and Phreesia suggests positive industry sentiment, potentially signaling growth opportunities or increased investor interest in these companies.

Source: Zacks Investment Research
Market Sentiment: Neutral
ENOV stock latest news image
Quick Summary

Stocks in the Medical Info Systems industry, including Enovis, Omnicell, and Phreesia, are anticipated to benefit from advancements in GenAI technology.

Why It Matters

Stocks in the Zacks Medical Info Systems industry are poised for growth, driven by advancements in GenAI, signaling potential profitability and innovation in healthcare technology investments.

Source: Zacks Investment Research
Market Sentiment: Positive
ENOV stock latest news image
Quick Summary

Enovis announced that Davide Visentin will replace Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025.

Why It Matters

Leadership changes can impact a company's strategic direction and operational effectiveness, influencing investor confidence and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
ENOV stock latest news image
Quick Summary

Enovis Corporation (NYSE: ENOV) will present at the J.P. Morgan Healthcare Conference on January 13, 2025, at 9:45 a.m. PST. Details will be available on their website.

Why It Matters

Enovis Corporation's presentation at a major healthcare conference signals potential insights into its growth strategy and innovations, impacting investor sentiment and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
ENOV stock latest news image
Quick Summary

Maplebear Inc. (CART) will replace Enovis Corp. (ENOV) in the S&P MidCap 400, while Enovis will take Arch Resources' place in the S&P SmallCap 600, effective January 14, 2025.

Why It Matters

Maplebear's addition to the S&P MidCap 400 may boost its stock price due to increased visibility, while Enovis' shift to the SmallCap 600 reflects changes in market capitalization that could affect investor sentiment.

Source: PRNewsWire
Market Sentiment: Neutral
ENOV stock latest news image
Quick Summary

Enovis Corporation reported strong Q3 results on November 6, prompting analysts to maintain Buy ratings with price targets of $62 to $75, boosted by a recent acquisition.

Why It Matters

Enovis Corporation's strong Q3 results and analyst Buy ratings indicate positive sentiment and potential stock appreciation, supported by growth from acquisitions and favorable valuations.

Source: Seeking Alpha
Market Sentiment: Positive

Frequently Asked Questions About ENOV Stock

What is Enovis Corporation's (ENOV) stock forecast for 2025?

Based on our analysis of 17 Wall Street analysts, Enovis Corporation (ENOV) has a median price target of $63.50. The highest price target is $75.00 and the lowest is $50.00.

Is ENOV stock a good investment in 2025?

According to current analyst ratings, ENOV has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $44.00. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for ENOV stock?

Wall Street analysts predict ENOV stock could reach $63.50 in the next 12 months. This represents a 44.3% increase from the current price of $44.00. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Enovis Corporation's business model?

Enovis Corporation generates revenue through the manufacture and distribution of medical devices for reconstructive surgery, rehabilitation, and pain management. It operates in two main segments: Prevention and Recovery, which offers a variety of orthopedic and recovery solutions, and Reconstructive, which focuses on surgical implants and productivity tools. The company sells its products through independent distributors and directly under its ESAB and DJO brands.

What is the highest forecasted price for ENOV Enovis Corporation?

The highest price target for ENOV is $75.00 from Caitlin Cronin at Canaccord Genuity, which represents a 70.5% increase from the current price of $44.00.

What is the lowest forecasted price for ENOV Enovis Corporation?

The lowest price target for ENOV is $50.00 from Robbie Marcus at JP Morgan, which represents a 13.6% increase from the current price of $44.00.

What is the overall ENOV consensus from analysts for Enovis Corporation?

The overall analyst consensus for ENOV is bullish. Out of 17 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $63.50.

How accurate are ENOV stock price projections?

Stock price projections, including those for Enovis Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.